Protein Kinase Inhibitors: all 15,278 studies that test it

Page 52 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Sunitinib for Advanced Thymus Cancer Following Earlier TreatmentCompletedNCT01621568Phase 2Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF InhibitorCompletedNCT01619774Phase 2Results posted
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Phase 3Results posted
• Ibrutinib (PCI-32765) in Waldenstrom's MacroglobulinemiaCompletedNCT01614821Phase 2Results posted
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 2Results posted
• A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins LymphomaCompletedNCT01614197Phase 1Results posted
• Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral SurgeryCompletedNCT01612351Phase 2Results posted
• Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or StomachCompletedNCT01611857Phase 1/2Results posted
• A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01611090Phase 3Results posted
• A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentCompletedNCT01610336Phase 2Results posted
• Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase InhibitorCompletedNCT01610284Phase 3Results posted
• A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian CancerCompletedNCT01610206Phase 2Results posted
• A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsCompletedNCT01609543Phase 4Results posted
• Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung CancerCompletedNCT01605916Phase 1Results posted
• Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100CompletedNCT01605227Phase 3Results posted
• Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaCompletedNCT01604772Phase 2Results posted
• Study of MLN8237 in Combination With Irinotecan and TemozolomideCompletedNCT01601535Phase 1/2Results posted
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney CancerTerminatedNCT01599832Not applicableResults posted
• Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate CancerCompletedNCT01599793Phase 2Results posted
• Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk PatientsTerminatedNCT01599754Phase 3Results posted
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaCompletedNCT01597908Phase 3Results posted
• AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast CancerCompletedNCT01597388Phase 1Results posted
• Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast CancerCompletedNCT01596751Phase 1/2Results posted
• Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)CompletedNCT01596062Phase 2Results posted
• An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)CompletedNCT01595009Phase 4Results posted
• Ruxolitinib in Estrogen Receptor Positive Breast CancerCompletedNCT01594216Phase 2Results posted
• A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue SarcomaCompletedNCT01593748Phase 2Results posted
• Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to ImatinibCompletedNCT01593254Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal MesotheliomaCompletedNCT01592383Phase 2Results posted
• PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic LeukemiaActive, not recruitingNCT01589302Phase 2Results posted
• Cabozantinib in Advanced Solid MalignanciesCompletedNCT01588821Phase 2Results posted
• Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant LymphomaCompletedNCT01588548Phase 1Results posted
• Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination RegimenCompletedNCT01587040Phase 1/2Results posted
• A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)CompletedNCT01586624Phase 1Results posted
• Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600ETerminatedNCT01586195Phase 2Results posted
• A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaCompletedNCT01584648Phase 3Results posted
• A Study in Recurrent Glioblastoma (GB)CompletedNCT01582269Phase 2Results posted
• Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic CancerCompletedNCT01582191Phase 1Results posted
• Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib TosylateTerminatedNCT01582009Phase 1/2Results posted
• Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric CancerTerminatedNCT01579578Phase 2Results posted
• A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01578707Phase 3Results posted
• Hepatic Impairment Study For Crizotinib In Advanced Cancer PatientsCompletedNCT01576406Phase 1Results posted
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryActive, not recruitingNCT01575548Phase 3Results posted
• Tivantinib in Treating Patients With Recurrent or Metastatic Breast CancerCompletedNCT01575522Phase 2Results posted
• Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)CompletedNCT01573702Phase 2Results posted
• A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K ActivationCompletedNCT01572727Phase 2/3Results posted
• Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)TerminatedNCT01570868Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )CompletedNCT01569295Phase 3Results posted
• Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid ArthritisTerminatedNCT01569074Phase 2Results posted
• Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01565668Phase 2Results posted
• Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung AdenocarcinomaCompletedNCT01565538Phase 2Results posted
• Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid ArthritisCompletedNCT01563978Phase 2Results posted
• 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA TrialCompletedNCT01563354Phase 2Results posted
• Ruxolitinib in Patients With Breast CancerTerminatedNCT01562873Phase 2Results posted
• A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01562275Phase 1Results posted
• BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)CompletedNCT01562028Phase 2Results posted
• A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma PatientsCompletedNCT01561833Phase 1Results posted
• Linsitinib in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT01560260Phase 2Results posted
• A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01559363Phase 1/2Results posted
• Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)CompletedNCT01558739Phase 4Results posted
• Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaCompletedNCT01558661Phase 2Results posted
• Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT01557959Phase 2Results posted
• GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell CancerCompletedNCT01553851Phase 2Results posted
• Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant RecipientsCompletedNCT01551212Phase 4Results posted
• Buparlisib in Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT01551030Phase 2Results posted
• Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant RecipientsCompletedNCT01544491Phase 3Results posted
• A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy AloneCompletedNCT01544179Phase 3Results posted
• A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid TumorsCompletedNCT01543698Phase 1/2Results posted
• A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01539512Phase 3Results posted
• Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)TerminatedNCT01539291Phase 3Results posted
• A Study of LY3009104 in Healthy ParticipantsCompletedNCT01536951Phase 1Results posted
• Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436CompletedNCT01534897Not applicableResults posted
• Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive GenotypeCompletedNCT01534260Phase 1/2Results posted
• Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01533948Phase 2Results posted
• Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate CancerCompletedNCT01533246Phase 2Results posted
• Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung CancerCompletedNCT01533181Phase 2Results posted
• An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01532700Phase 2Results posted
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue SarcomaCompletedNCT01532687Phase 2Results posted
• Continuation Study of the Oral AKT Inhibitor GSK2110183CompletedNCT01531894Phase 2Results posted
• Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous TreatmentCompletedNCT01530334Phase 2Results posted
• A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different TreatmentsCompletedNCT01529112Phase 2Results posted
• Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast CancerTerminatedNCT01528345Phase 2Results posted
• Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsTerminatedNCT01526928Phase 1/2Results posted
• Topical Rapamycin to Erase Angiofibromas in TSCCompletedNCT01526356Phase 2Results posted
• Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid TumorsCompletedNCT01525602Phase 1Results posted
• A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsCompletedNCT01525550Phase 4Results posted
• A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersCompletedNCT01524978Phase 2Results posted
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)CompletedNCT01524783Phase 3Results posted
• Study of Dovitinib (TKI258) in Adenoid Cystic CarcinomaCompletedNCT01524692Phase 2Results posted
• LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyCompletedNCT01523587Phase 3Results posted
• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With RuxolitinibTerminatedNCT01523171Phase 2Results posted
• Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric CancerCompletedNCT01522768Phase 2Results posted
• Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsCompletedNCT01522469Phase 2Results posted
• Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerTerminatedNCT01522443Phase 3Results posted
• Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.CompletedNCT01520870Phase 2Results posted
• Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsCompletedNCT01520519Phase 2Results posted
• Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibTerminatedNCT01519427Phase 2Results posted
• Tivantinib in Treating Patients With Metastatic Prostate CancerCompletedNCT01519414Phase 2Results posted
• BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 MutationsTerminatedNCT01519323Phase 1Results posted

← Protein Kinase Inhibitors overview